New drug combo tested for tough cancers
NCT ID NCT04234113
First seen Apr 05, 2026 · Last updated Jun 15, 2026 · Updated 12 times
Summary
This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to see if the treatment was safe and to look for early signs of tumor shrinkage. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, France, 69379, France
-
Hopital Saint Louis
Paris, 75010, France
-
Hôpitaux Universitaires de Marseille Timone
Marseille, 13005, France
-
Institut Claudius Regaud
Toulouse, France, 31059, France
-
Institut Gustave Roussy
Paris, France, 94805, France
-
Institut de Cancerologie de L'Ouest
Saint-Herblain, 44805, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Masarykův Onkologický Ústav Brno Klinika komplexní onkologické péče
Brno, Czechia, 65653, Czechia
-
University Hospital Sanchinarro
Madrid, 28050, Spain
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15216, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain, 08035, Spain
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.